A Clinical Registry of Orthobiologics Procedures
Launched by REGENEXX, LLC · Jan 3, 2017
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This Registry was designed to assure that the benefits and knowledge gained by studying clinical outcomes associated with the use of percutaneous orthopedic procedures outweigh the potential risks to the patients. The primary objective of this Registry is to observe the improvements in subject-reported clinical outcomes for these procedures used to treat musculoskeletal disorders. Secondary objectives include evaluating post-treatment complication, adverse events, re-injections, and surgical intervention. Patients receiving percutaneous orthopedic treatments are asked to enroll before recei...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Candidates must meet ALL of the following:
- • 1. Voluntary signature of the IRB approved Informed Consents,
- • 2. Treated with a Regenexx procedure
- • 3. Have a musculoskeletal condition appropriate for the procedure such as osteoarthritis or internal joint derangement; ligament or tendon injury; intervertebral disc degeneration; protrusion, extrusion, or annular tear; muscle tear
- Exclusion Criteria:
- • none
About Regenexx, Llc
Regenexx, LLC is a leading clinical research organization specializing in innovative regenerative medicine therapies. Focused on developing advanced treatments for musculoskeletal conditions, the company employs cutting-edge techniques, including stem cell and platelet-rich plasma (PRP) therapies, to promote healing and improve patient outcomes. With a commitment to rigorous scientific research and ethical practices, Regenexx conducts clinical trials that aim to validate the safety and efficacy of its therapies, contributing to the advancement of regenerative medicine and enhancing quality of life for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Broomfield, Colorado, United States
Phoenix, Arizona, United States
Beverly Hills, California, United States
Oceanside, California, United States
San Rafael, California, United States
Thousand Oaks, California, United States
Van Nuys, California, United States
Broomfield, Colorado, United States
Sarasota, Florida, United States
Chicago, Illinois, United States
Des Plaines, Illinois, United States
Des Moines, Iowa, United States
Louisville, Kentucky, United States
Lafayette, Louisiana, United States
Chevy Chase, Maryland, United States
Waite Park, Minnesota, United States
Cedar Knolls, New Jersey, United States
Oakhurst, New Jersey, United States
Wayne, New Jersey, United States
New York, New York, United States
Cincinnati, Ohio, United States
Toledo, Ohio, United States
Tulsa, Oklahoma, United States
Hood River, Oregon, United States
Pittsburgh, Pennsylvania, United States
Springfield, Pennsylvania, United States
Dallas, Texas, United States
South Jordan, Utah, United States
Winooski, Vermont, United States
Mclean, Virginia, United States
Kingswood, New South Wales, Australia
Hyderabad, Telangana, India
Patients applied
Trial Officials
Christopher Centeno, MD
Principal Investigator
Regenerative Sciences, LLC and Centeno-Schultz Clinic
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials